Nav: Home

Longer survival of advanced cancer patients given methylnaltrexone for constipation suggests role for mu opiate receptor in cancer progression

September 01, 2016

A study of advanced cancer patients published in the journal Annals of Oncology and presented at this year's World Congress of Anaesthesiologists in Hong Kong suggests that opioid painkillers and their receptor in cells - the mu opiate receptor - could be involved in cancer progression, and could thus be a target for treatments. The study is by Dr Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Dr Jonathan Moss, University of Chicago, IL, USA and colleagues.

Methylnaltrexone (MNTX) is approved in the USA and more than 50 other countries for treatment of opioid induced constipation (OIC). MNTX works by binding to the mu opioid receptor (MOR) in periphery, thereby blocking opioid drugs from binding to that same receptor. It does not cross into the brain, preserving centrally mediated pain relief while reversing the constipation caused by peripheral MORs in the gut. By acting in this way, MNTX is termed a 'peripherally acting mu opioid receptor antagonist'.

In this study, the authors pooled data from two placebo controlled randomised clinical trials of MNTX given by subcutaneous injection. In these trials, 229 patients with advanced cancer, treated with opioids for pain relief, and suffering OIC despite laxative treatment were randomised to MNTX or placebo. These patients were analyzed for overall survival (OS) in an unplanned post-trial analysis called a 'post-hoc' analysis. MNTX or placebo were given subcutaneously during the double blind phase of these studies, which was followed by an open label phase in which around half of patients originally on placebo switched to MNTX treatment.

Treatment with MNTX resulted in median OS of 76 days compared to 56 days in those given placebo (statistically significant); when looking specifically at responders to MNTX treatment (those able to defecate after treatment), these survived a median of 118 days compared to 55 days for non-responders (also statistically significant).

The authors say that the direct effect of MNTX on cancer progression is the most likely reason for increased survival, because neither treatment nor response to MNTX led to longer survival in 134 seriously ill non-cancer patients enrolled in the same trials. If the drug showed an overall survival benefit largely due to its effects on the gastrointestinal system, then then all patients would expected to benefit, not just the cancer patients.

They add: "Our results show that treatment with MNTX, and even more so response to MNTX are associated with increased overall survival in advanced cancer patients, which supports our earlier preclinical hypothesis that the mu receptor can play a role in cancer progression. Targeting this receptor with MNTX warrants further investigation in cancer therapy." This human study is consistent with more than a decade of molecular, cellular and animal studies by Dr Moss' team at the University of Chicago and other teams elsewhere.

The authors say: "To our knowledge this is the first human demonstration of improved OS for cancer patients following treatment with peripheral opioid antagonists...our data suggest that MNTX treatment in advanced cancer patients can prolong survival, plausibly through reduction of opioid induced mu receptor signaling."

However they conclude: "Our findings should be interpreted as preliminary, hypothesis generating, and not enough at this stage to suggest changes to clinical practice, where pain control remains an important issue. Prospective studies to confirm the role of MNTX in advanced cancer patients are warranted to confirm clinical relevance of our findings."

In a linked comment published with the article, Professor Stein Kassa, Professor Per Sjørgen and Professor Stein Kassa, Norwegian University of Science and Technology, Trondheim, and Cancer Clinic, Trondheim University Hospital, Norway, say: "There is a pronounced need for investigating mu receptor mediated opioid effects on tumour biology and disease stages as well as effects of opioid type, dose and exposure in different settings."
-end-


World Federation of Societies of Anaesthesiologists

Related Cancer Patients Articles:

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.
The art of cancer caregiving: How art therapies benefits those caring for cancer patients
A recent Drexel University study showed coloring and open-studio art therapy benefits stressed caregivers of cancer patients.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer tissue-freezing approach may help more breast cancer patients in lower income countries
A new reusable device created by the Johns Hopkins University can help women with breast cancer in lower income countries by using carbon dioxide, a widely available and affordable gas, to power a cancer tissue-freezing probe instead of industry-standard argon.
Lots of patients with cancer, cancer survivors use but don't report complementary/alternative medicine therapies
This study used data from a nationwide survey to estimate how many patients with cancer and cancer survivors use complementary and alternative medicines (CAMS) in addition to or instead of conventional therapies, and how many don't disclose that to their physicians.
Colorectal cancer in patients with early onset is distinct from that in older patients
New research indicates that colorectal cancer diagnosed at an early age has clinical and genetic features that are different from those seen in traditional colorectal cancer diagnosed later in life.
Comparable risk of recurrent venous thromboembolism between patients with unprovoked venous thromboembolism and patients with cancer
Patients with venous thromboembolism (VTE) carry a high risk of recurrence.
Personalized cancer vaccine may increase long-term survival in patients with deadly brain cancer
An international Phase III study led by researchers at UCLA has found that a personalized GBM vaccine may increase long-term survival in some patients.
Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
Patients with blood cancer precursor at risk of developing cancer even after 30 years
Patients with monoclonal gammopathy of undetermined significance are at risk of progressing to multiple myeloma or a related cancer -- even after 30 years of stability.
More Cancer Patients News and Cancer Patients Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.